Drug Trial Radar · NCT06608641
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
490
Planned (sponsor's estimate)
Start
Mar 19, 2024
Primary completion
Jun 2025
Study completion Dec 2025
Sponsor
- Lead sponsor
- Jina Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Novum Pharmaceutical Research Services
- First posted
- Sep 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bipolar disorder (BPD) is a chronic debilitating illness characterized by drastic swings in mood, energy and functional ability that affects the adult population. Endoxifen is an active metabolite of the marketed drug Tamoxifen and the present study aims to evaluate the efficacy and safety of 8 mg endoxifen in the Bipolar I disorder patient population compared to a placebo arm. Endoxifen will be compared to a placebo to demonstrate that the test product is active and to establish that the study is sufficiently sensitive to detect differences between the investigational products. Thus, Endoxifen will be compared to placebo to demonstrate that the test product is safe and active.
Conditions
- Bipolar 1 Disorder
Interventions
Endoxifen enteric-coated tablet (8 mg)Drug
Patients will continue treatment with their initial randomized medication for 3 weeks
Placebo TabletsDrug
Patients will be treated with Endoxifen Placebo Tablets for 21 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy - mean change from baseline to Day 21 in the total YMRS scoreTime frame: 27 days
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Synexus
Cerritos, California
NRC Research Institute
Los Angeles, California
NRC Research Institute
Orange, California
Medical Research of Westchester, Inc.
Miami, Florida
Sunshine Medical Research Studies Inc.
Miami, Florida
Innovative Clinical Research, Inc.
Miami Lakes, Florida
South Florida Research Phase I-IV, Inc.
Miami Springs, Florida
Santos Research Center, CORP
Tampa, Florida
Accelerated Clinical Trials, LLC
East Point, Georgia
Accelerated Clinical Trials, LLC
Norcross, Georgia
Accelerated Clinical Trials, LLC
Peachtree Corners, Georgia
Precise Research Centers
Flowood, Mississippi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.